AstraZeneca PLC ranks slightly below the peer group median, with a relatively even profile across the main dimensions. Price action is lagging the structural profile — current market behavior is not yet confirming the structural position.
Peer-relative scores, weakest to strongest
AstraZeneca is a global biopharmaceutical company focused on prescription medicines, particularly in oncology, cardiovascular, and respiratory diseases. The group operates worldwide with a broad portfolio of innovative and biologic drugs.
Strong profitability metrics such as a 19.33% ROIC and a 21.6% operating margin anchor AstraZeneca at the high end of capital efficiency, yet the premium valuation (score: 19/100) is limited by persistent market confidence and expectation risk. The company’s robust earnings base is evidenced by €10.2bn in net income and 4.1% year-over-year revenue growth, both supporting the quality case. However, a stability score of 64/100 signals moderate risk containment—enough to avoid a confidence break, but not enough to fully justify the premium. The consensus analyst rating of Moderate Buy and a 12-month price target of $102.67 are positive signals, but remain secondary to the core issue: expectation risk and competitive threats continue to weigh on sentiment.
External context complicates the picture rather than resolving it. AstraZeneca’s Q4 2025 revenue and EPS both slightly missed analyst estimates, highlighting the ongoing risk that even near-expected results can disappoint a market primed for outperformance. Competitive pressures from biosimilars and innovative therapies—particularly in biologics-heavy segments—are more acute for AstraZeneca than for some peers, while regulatory changes around pricing and patents may impact its product and geographic mix more directly. These factors reinforce that the premium is not yet fully protected.
Compared to peers, AstraZeneca’s profitability is strong but not unique—companies like Novartis and ALK-Abelló also post high quality scores. What stands out is that AstraZeneca’s premium valuation is higher than many peers, except for select high-growth outliers. This position is partly driven by factors more specific to AstraZeneca, such as its exposure to biologics and regulatory risk, rather than sector-wide dynamics.
A more defensible premium would require market confidence to stabilize and expectation risk to moderate. Supporting improvement would include successful product launches that address competitive threats and clearer resilience to regulatory shifts. Until then, AstraZeneca carries a valuation not yet fully anchored.
Break down AZN.L's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.